Clinical Trials Browser

Approved for marketing × INDUSTRY × Glioma × Clear all

Glioma

NCT05592743 2024-11-05

Vorasidenib Expanded Access Program

Astrocytoma, Glioma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Oligodendroglioma, Pathologic Processes, Recurrence, Neuroectodermal Tumors, Neoplasms, Neuroepithelial, Disease Attributes

NCT05760586 2024-08-12

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

Approved for marketing

CNS

Glioma, Neoplasms

Clinical Trials

Intermediate-size Expanded Access to ONC201 for Patients With H3 K27M-mutant and/or Midline Gliomas

Vorasidenib Expanded Access Program

Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma